BCX5191 Articles
BioCryst Pharma restructures in face of pipeline disappointments
10 December 2012
BioCryst withdraws BCX5191 lND following discussion with FDA
4 November 2012
Showing 1-2 of 2 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
